|
|
|
|
| LEADER |
04497nma a2201309 u 4500 |
| 001 |
EB001991764 |
| 003 |
EBX01000000000000001154666 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210512 ||| eng |
| 020 |
|
|
|a 9783039280704
|
| 020 |
|
|
|a books978-3-03928-071-1
|
| 020 |
|
|
|a 9783039280711
|
| 100 |
1 |
|
|a Tikkanen, Ritva
|
| 245 |
0 |
0 |
|a Mitogen Activated Protein Kinases
|h Elektronische Ressource
|b Functions in Signal Transduction and Human Diseases
|
| 260 |
|
|
|a Basel, Switzerland
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2020
|
| 300 |
|
|
|a 1 electronic resource (276 p.)
|
| 653 |
|
|
|a mitochondrial dysfunction
|
| 653 |
|
|
|a sunitinib
|
| 653 |
|
|
|a gastric ulcer
|
| 653 |
|
|
|a SR
|
| 653 |
|
|
|a MAPK kinetics
|
| 653 |
|
|
|a angiogenesis
|
| 653 |
|
|
|a cell cycle
|
| 653 |
|
|
|a JNK
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a psoriasis
|
| 653 |
|
|
|a MAPK
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a protein-protein interaction (PPI)
|
| 653 |
|
|
|a porcine intestinal epithelial cell
|
| 653 |
|
|
|a extracellular signal-regulated kinase 5 (ERK5)
|
| 653 |
|
|
|a phosphorylation
|
| 653 |
|
|
|a cecropin A
|
| 653 |
|
|
|a JNKs
|
| 653 |
|
|
|a erlotinib
|
| 653 |
|
|
|a infantile myofibromatosis
|
| 653 |
|
|
|a cytokines
|
| 653 |
|
|
|a receptor tyrosine kinases
|
| 653 |
|
|
|a mitochondria
|
| 653 |
|
|
|a aortic valve stenosis
|
| 653 |
|
|
|a downregulation
|
| 653 |
|
|
|a Rabdosia inflexa
|
| 653 |
|
|
|a protein kinase inhibitors
|
| 653 |
|
|
|a bronchopulmonary dysplasia
|
| 653 |
|
|
|a antimicrobial peptide
|
| 653 |
|
|
|a ROS
|
| 653 |
|
|
|a U0126
|
| 653 |
|
|
|a FRS2
|
| 653 |
|
|
|a DUSP1
|
| 653 |
|
|
|a HPAECs
|
| 653 |
|
|
|a ERK1/2
|
| 653 |
|
|
|a SIRT1
|
| 653 |
|
|
|a neurodegeneration
|
| 653 |
|
|
|a DAPK
|
| 653 |
|
|
|a apoptosis
|
| 653 |
|
|
|a p38 MAPK
|
| 653 |
|
|
|a aortic valve sclerosis
|
| 653 |
|
|
|a MKK4
|
| 653 |
|
|
|a reactive oxygen species
|
| 653 |
|
|
|a platelet-derived growth factor receptor
|
| 653 |
|
|
|a Research & information: general / bicssc
|
| 653 |
|
|
|a atherosclerosis
|
| 653 |
|
|
|a tight junction protein
|
| 653 |
|
|
|a osteoclast differentiation
|
| 653 |
|
|
|a Biology, life sciences / bicssc
|
| 653 |
|
|
|a CR
|
| 653 |
|
|
|a NF-κB
|
| 653 |
|
|
|a naphthalimide-metal complex conjugates
|
| 653 |
|
|
|a FR180204
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a T2DM
|
| 653 |
|
|
|a Kv4.2
|
| 653 |
|
|
|a N-heterocyclic carbene
|
| 653 |
|
|
|a p53
|
| 653 |
|
|
|a SRC
|
| 653 |
|
|
|a FGF-induced signaling
|
| 653 |
|
|
|a PTPN6
|
| 653 |
|
|
|a metabolic profiling
|
| 653 |
|
|
|a mitogen-activated protein kinase pathway (MAPK pathway)
|
| 653 |
|
|
|a p38
|
| 653 |
|
|
|a mitogen-activated protein kinases (MAPKs)
|
| 653 |
|
|
|a MAPK/PI3K/Akt signaling pathway
|
| 653 |
|
|
|a ERK
|
| 653 |
|
|
|a extracellular signal-regulated kinases 1/2
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a Parkinson's disease
|
| 653 |
|
|
|a DOK4
|
| 653 |
|
|
|a MKK7
|
| 653 |
|
|
|a SIRT2
|
| 653 |
|
|
|a p38 MAPKs
|
| 653 |
|
|
|a hyperoxia
|
| 653 |
|
|
|a protein tyrosine phosphatase interacting protein 51 (PTPIP51)
|
| 653 |
|
|
|a neuro-inflammation
|
| 653 |
|
|
|a bone remodeling
|
| 653 |
|
|
|a targeted therapy
|
| 653 |
|
|
|a cancer signaling
|
| 653 |
|
|
|a Compatibility
|
| 653 |
|
|
|a PC12 cells
|
| 653 |
|
|
|a MEK/ERK signaling
|
| 700 |
1 |
|
|a Nikolic-Paterson, David
|
| 700 |
1 |
|
|a Tikkanen, Ritva
|
| 700 |
1 |
|
|a Nikolic-Paterson, David
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-03928-071-1
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/68643
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/2405
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 000
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Mitogen-activated protein kinases (MAPK) are a large family of enzymes that function as signal transducers to regulate a diverse range of physiological responses. However, signaling via extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK), and p38 MAPK also underpin many disease processes. This Special Issue provides new insights into how MAPK signaling contributes to specific pathological processes across a range of conditions, including disorders of lung development, type 2 diabetes, proliferative skin diseases, cardiovascular diseases, and neurological diseases.
|